Cellular and molecular analysis of the skeletal pathologies associated with muco...
Cellular and molecular analysis of the skeletal pathologies associated with mucopolysaccharidosis VI MPS VI
Mucopolysaccharidosis-VI (MPS-VI) is a lysosomal storage disorder predominantly affecting skeletal remodelling and caused by pathogenic mutations in the ARSB gene, encoding the glycosaminoglycan-degrading enzyme arylsulfatase B. P...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
.BLASTED2
Identification of molecular targets for the treatment of the...
100K€
Cerrado
RE-STORE
Pharmacological restoration of selective autophagy for the t...
150K€
Cerrado
EUCLYD
A European Consortium for Lysosomal Disorders
4M€
Cerrado
RTC-2016-5686-1
Desarrollo de tratamientos para enfermedades raras de depósi...
323K€
Cerrado
RTI2018-098672-B-I00
TERAPIA GENICA NO VIRAL PARA EL TRATAMIENTO DE ENFERMEDADES...
145K€
Cerrado
SAF2014-56562-R
IDENTIFICACION DE VARIANTES, GENERACION DE MODELOS Y ENSAYOS...
121K€
Cerrado
Información proyecto LYSOBONE
Duración del proyecto: 24 meses
Fecha Inicio: 2018-02-21
Fecha Fin: 2020-02-29
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Mucopolysaccharidosis-VI (MPS-VI) is a lysosomal storage disorder predominantly affecting skeletal remodelling and caused by pathogenic mutations in the ARSB gene, encoding the glycosaminoglycan-degrading enzyme arylsulfatase B. Preliminary analysis of Arsb-deficient mice unraveled a skeletal phenotype of similar severity and with lysosomal storage defects in different skeletal cell types. This Arsb-deficient mouse model therefore provides an excellent tool to understand the skeletal and non-skeletal pathologies related to MPS-VI and to address the clinically relevant question, if enzyme replacement therapy (ERT) can influence the existing (non-)skeletal pathologies in lysosomal storage disorders. Moreover, another major objective is to unravel the cellular consequences of Arsb-deficiency on a molecular level and to investigate mechanisms of ARSB uptake and lysosomal delivery in different primary cell types of Arsb-deficient mice. This project will therefore certainly generate knowledge with relevance for other (skeletal) disorders as well, as the cellular defects in MPS-VI are closely linked to that of two of the most prevalent disorders in the European Union, i.e. osteoporosis and osteoarthritis. Next to its scientific goals, this proposal aims to offer a broad personal training program for me as a postdoctoral researcher as well. Handling this project will not only offer an intensive scientific training (intellectual-methodological), but also improve my skills regarding project management (administrative-financial) and writing. As a two-way transfer, my previously acquired knowledge on the genetics of skeletal disorders and related experimental skills will be transferred to the host organization. A final goal of this proposal is to disseminate the acquired data towards specialized scientific audiences (scientific conferences and publications) and propagate these data towards non-expert audiences (patient meetings, press releases) as well.